Denali Therapeutics' (DNLI) Buy Rating Reiterated at B. Riley

Denali Therapeutics (NASDAQ:DNLI - Get Free Report)'s stock had its "buy" rating reissued by B. Riley in a report issued on Wednesday,Benzinga reports. They currently have a $35.00 price target on the stock, down from their prior price target of $38.00. B. Riley's price objective points to a potential upside of 109.71% from the company's current price. B. Riley also issued estimates for Denali Therapeutics' Q2 2025 earnings at ($0.80) EPS, FY2025 earnings at ($2.72) EPS, FY2026 earnings at ($2.48) EPS, FY2027 earnings at ($1.38) EPS, FY2028 earnings at ($2.05) EPS and FY2029 earnings at $0.87 EPS.

A number of other equities research analysts also recently issued reports on DNLI. The Goldman Sachs Group cut their target price on shares of Denali Therapeutics from $45.00 to $40.00 and set a "buy" rating for the company in a research report on Tuesday, January 28th. Robert W. Baird began coverage on shares of Denali Therapeutics in a research report on Tuesday, January 7th. They issued an "outperform" rating and a $31.00 target price for the company. HC Wainwright increased their target price on shares of Denali Therapeutics from $80.00 to $87.00 and gave the stock a "buy" rating in a research report on Friday, February 28th. William Blair reiterated an "outperform" rating on shares of Denali Therapeutics in a research report on Friday, February 28th. Finally, Oppenheimer dropped their price target on shares of Denali Therapeutics from $50.00 to $42.00 and set an "outperform" rating on the stock in a research note on Monday, March 3rd. Two research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $37.27.

Remove Ads

Denali Therapeutics Stock Performance

Shares of NASDAQ:DNLI traded up $0.42 during mid-day trading on Wednesday, hitting $16.69. The stock had a trading volume of 1,620,980 shares, compared to its average volume of 1,004,537. The company has a market cap of $2.42 billion, a PE ratio of -6.05 and a beta of 1.46. Denali Therapeutics has a 12-month low of $14.01 and a 12-month high of $33.33. The company's 50 day moving average is $20.80 and its 200-day moving average is $24.30.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.67) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.08. On average, equities research analysts predict that Denali Therapeutics will post -2.71 EPS for the current fiscal year.

Insider Activity at Denali Therapeutics

In other Denali Therapeutics news, Director Steve E. Krognes sold 3,339 shares of the firm's stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $20.81, for a total value of $69,484.59. Following the sale, the director now directly owns 25,757 shares in the company, valued at $536,003.17. This trade represents a 11.48 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Vicki L. Sato sold 3,080 shares of the firm's stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $20.91, for a total transaction of $64,402.80. Following the completion of the sale, the director now owns 107,976 shares in the company, valued at $2,257,778.16. This represents a 2.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 47,940 shares of company stock worth $973,442. 7.90% of the stock is owned by insiders.

Institutional Trading of Denali Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Victory Capital Management Inc. grew its position in Denali Therapeutics by 163.7% in the 3rd quarter. Victory Capital Management Inc. now owns 39,900 shares of the company's stock worth $1,162,000 after purchasing an additional 24,767 shares during the last quarter. FMR LLC lifted its holdings in shares of Denali Therapeutics by 3,234.3% during the 3rd quarter. FMR LLC now owns 7,831,378 shares of the company's stock worth $228,128,000 after acquiring an additional 7,596,508 shares during the period. Algert Global LLC lifted its holdings in shares of Denali Therapeutics by 82.4% during the 3rd quarter. Algert Global LLC now owns 48,630 shares of the company's stock worth $1,417,000 after acquiring an additional 21,975 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of Denali Therapeutics by 6.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 235,386 shares of the company's stock worth $6,857,000 after acquiring an additional 14,324 shares during the period. Finally, Principal Financial Group Inc. lifted its holdings in shares of Denali Therapeutics by 13.8% during the 3rd quarter. Principal Financial Group Inc. now owns 1,238,476 shares of the company's stock worth $36,076,000 after acquiring an additional 149,939 shares during the period. 92.92% of the stock is currently owned by institutional investors and hedge funds.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.